Mirae Asset Global ETFs Holdings
CTNM

Mirae Asset Global ETFs Holdings’s Contineum Therapeutics CTNM Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,094
Closed -$42.5K – 3289
2025
Q1 		$42.5K Buy
6,094
+234
+4% +$2.13K ﹤0.01% 2874
2024
Q4 		$85.8K Buy
5,860
+2,783
+90% +$44.1K ﹤0.01% 2760
2024
Q3 		$58.9K Buy
+3,077
New +$59K ﹤0.01% 2887

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CTNM Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 6,094 shares — an estimated $42.5K sold.

Mirae Asset Global ETFs Holdings first reported a position in CTNM in Q3 2024 and held it in 3 quarters. The position peaked at $85.8K in Q4 2024. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 6,094 Contineum Therapeutics shares in Q2 2025, an estimated $42.5K.
  • Mirae Asset Global ETFs Holdings first reported a position in Contineum Therapeutics in Q3 2024 and held it in 3 quarters.
  • Mirae Asset Global ETFs Holdings's Contineum Therapeutics position peaked at $85.8K in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.